Cover Image
市場調查報告書

粉末定量噴霧吸入器:醫療設備的開發平台評估

Dry Powder Inhaler Devices - Medical Devices Pipeline Assessment, 2017

出版商 GlobalData 商品編碼 357851
出版日期 內容資訊 英文 246 Pages
訂單完成後即時交付
價格
Back to Top
粉末定量噴霧吸入器:醫療設備的開發平台評估 Dry Powder Inhaler Devices - Medical Devices Pipeline Assessment, 2017
出版日期: 2017年07月01日 內容資訊: 英文 246 Pages
簡介

本報告提供粉末定量噴霧吸入器相關之開發中產品調查,提供您各開發階段趨勢和產品的主要開發企業,現在進行中的臨床實驗,產業的近幾年趨勢等資訊。

第1章 目錄

第2章 簡介

  • 粉末定量噴霧吸入器概要

第3章 開發中的產品

  • 粉末定量噴霧吸入器 - 開發中產品:各開發階段
  • 粉末定量噴霧吸入器 - 開發中產品:各地區 (國家)
  • 粉末定量噴霧吸入器 - 開發中產品:各法規途徑
  • 粉末定量噴霧吸入器 - 開發中產品:各核准時期 (估計)
  • 粉末定量噴霧吸入器 - 持續中臨床實驗

第4章 粉末定量噴霧吸入器 - 正在開發的開發中產品:各企業

  • 粉末定量噴霧吸入器企業 - 開發中產品:各開發階段
  • 粉末定量噴霧吸入器 - 開發中產品:各開發階段

第5章 粉末定量噴霧吸入器 開發企業與產品概要

  • Acorda Therapeutics, Inc.
  • Adamis Pharmaceuticals Corporation
  • Advent Pharmaceuticals Pty Ltd
  • Aespira Ltd.
  • AKELA Pharma Inc. (Inactive)
  • Bayer HealthCare AG
  • Bespak Europe Ltd.
  • GlaxoSmithKline Plc
  • Hovione FarmaCiencia SA
  • MannKind Corporation
  • Nanotherapeutics, Inc.
  • Nektar Therapeutics
  • Novartis AG
  • OPKO Health, Inc.
  • Pharmaxis Limited
  • Respira Therapeutics, Inc.
  • Sandoz International GmbH
  • Sheffield Hallam University
  • 新日本科學
  • Teva Pharmaceutical Industries Ltd.
  • University of Kansas
  • University of Texas Medical Branch at Galveston

第6章 粉末定量噴霧吸入器 - 近幾年趨勢

第7章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

GlobalData's Medical Devices sector report, "Dry Powder Inhaler Devices - Medical Devices Pipeline Assessment, 2017" provides an overview of Dry Powder Inhaler Devices currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Dry Powder Inhaler Devices pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Dry Powder Inhaler Devices under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Dry Powder Inhaler Devices and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Dry Powder Inhaler Devices under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1 Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 7
  • 1.2 List of Figures 9

2 Introduction 10

  • 2.1 Dry Powder Inhaler Devices Overview 10

3 Products under Development 11

  • 3.1 Dry Powder Inhaler Devices - Pipeline Products by Stage of Development 11
  • 3.2 Dry Powder Inhaler Devices - Pipeline Products by Territory 12
  • 3.3 Dry Powder Inhaler Devices - Pipeline Products by Regulatory Path 13
  • 3.4 Dry Powder Inhaler Devices - Pipeline Products by Estimated Approval Date 14
  • 3.5 Dry Powder Inhaler Devices - Ongoing Clinical Trials 15

4 Dry Powder Inhaler Devices - Pipeline Products under Development by Companies 16

  • 4.1 Dry Powder Inhaler Devices Companies - Pipeline Products by Stage of Development 16
  • 4.2 Dry Powder Inhaler Devices - Pipeline Products by Stage of Development 18

5 Dry Powder Inhaler Devices Companies and Product Overview 19

  • 5.1 Acorda Therapeutics Inc Company Overview 19
    • 5.1.1 Acorda Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 19
  • 5.2 Adamis Pharmaceuticals Corp Company Overview 23
    • 5.2.1 Adamis Pharmaceuticals Corp Pipeline Products & Ongoing Clinical Trials Overview 23
  • 5.3 Advent Pharmaceuticals Pty Ltd Company Overview 24
    • 5.3.1 Advent Pharmaceuticals Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview 24
  • 5.4 Aespira Ltd. Company Overview 25
    • 5.4.1 Aespira Ltd. Pipeline Products & Ongoing Clinical Trials Overview 25
  • 5.5 AKELA Pharma Inc. (Inactive) Company Overview 26
    • 5.5.1 AKELA Pharma Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 26
  • 5.6 Bayer HealthCare AG (Inactive) Company Overview 27
    • 5.6.1 Bayer HealthCare AG (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 27
  • 5.7 Bespak Europe Ltd Company Overview 28
    • 5.7.1 Bespak Europe Ltd Pipeline Products & Ongoing Clinical Trials Overview 28
  • 5.8 Boehringer Ingelheim GmbH Company Overview 29
    • 5.8.1 Boehringer Ingelheim GmbH Pipeline Products & Ongoing Clinical Trials Overview 29
  • 5.9 Circassia Pharmaceuticals Plc Company Overview 30
    • 5.9.1 Circassia Pharmaceuticals Plc Pipeline Products & Ongoing Clinical Trials Overview 30
  • 5.10 GlaxoSmithKline Plc Company Overview 31
    • 5.10.1 GlaxoSmithKline Plc Pipeline Products & Ongoing Clinical Trials Overview 31
  • 5.11 MannKind Corp Company Overview 36
    • 5.11.1 MannKind Corp Pipeline Products & Ongoing Clinical Trials Overview 36
  • 5.12 Monash University Company Overview 37
    • 5.12.1 Monash University Pipeline Products & Ongoing Clinical Trials Overview 37
  • 5.13 Nanotherapeutics Inc Company Overview 38
    • 5.13.1 Nanotherapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 38
  • 5.14 Nektar Therapeutics Company Overview 40
    • 5.14.1 Nektar Therapeutics Pipeline Products & Ongoing Clinical Trials Overview 40
  • 5.15 Novartis AG Company Overview 41
    • 5.15.1 Novartis AG Pipeline Products & Ongoing Clinical Trials Overview 41
  • 5.16 OPKO Health Inc Company Overview 45
    • 5.16.1 OPKO Health Inc Pipeline Products & Ongoing Clinical Trials Overview 45
  • 5.17 Pharmaxis Ltd Company Overview 46
    • 5.17.1 Pharmaxis Ltd Pipeline Products & Ongoing Clinical Trials Overview 46
  • 5.18 Respira Therapeutics Inc Company Overview 47
    • 5.18.1 Respira Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 47
  • 5.19 Sandoz International GmbH Company Overview 48
    • 5.19.1 Sandoz International GmbH Pipeline Products & Ongoing Clinical Trials Overview 48
  • 5.20 Sheffield Hallam University Company Overview 50
    • 5.20.1 Sheffield Hallam University Pipeline Products & Ongoing Clinical Trials Overview 50
  • 5.21 Shin Nippon Biomedical Laboratories Ltd Company Overview 51
    • 5.21.1 Shin Nippon Biomedical Laboratories Ltd Pipeline Products & Ongoing Clinical Trials Overview 51
  • 5.22 Sun Pharma Advanced Research Company Ltd Company Overview 52
    • 5.22.1 Sun Pharma Advanced Research Company Ltd Pipeline Products & Ongoing Clinical Trials Overview 52
  • 5.23 Teva Pharmaceutical Industries Ltd Company Overview 54
    • 5.23.1 Teva Pharmaceutical Industries Ltd Pipeline Products & Ongoing Clinical Trials Overview 54
  • 5.24 University of Kansas Company Overview 59
    • 5.24.1 University of Kansas Pipeline Products & Ongoing Clinical Trials Overview 59
  • 5.25 University of Texas Medical Branch at Galveston Company Overview 60
    • 5.25.1 University of Texas Medical Branch at Galveston Pipeline Products & Ongoing Clinical Trials Overview 60
  • 5.26 Vectura Group Plc Company Overview 61
    • 5.26.1 Vectura Group Plc Pipeline Products & Ongoing Clinical Trials Overview 61
  • 5.27 Verona Pharma Plc Company Overview 62
    • 5.27.1 Verona Pharma Plc Pipeline Products & Ongoing Clinical Trials Overview 62
  • 5.28 Virginia Commonwealth University Company Overview 63
    • 5.28.1 Virginia Commonwealth University Pipeline Products & Ongoing Clinical Trials Overview 63

6 Dry Powder Inhaler Devices- Recent Developments 64

  • 6.1 Jun 20, 2017: Peter H. Khoury, Ph.D., MBA Appointed President and Chief Executive Officer of Nanotherapeutics 64
  • 6.2 Jun 19, 2017: GSK confirms start date for Luke Miels 64
  • 6.3 Jun 15, 2017: Consort Medical: Full year results 64
  • 6.4 Jun 14, 2017: SPARC Announces Top-line Results of Pivotal Peak Inspiratory Flow (PIF) study and Low Dose Pharmacokinetic (PK) Study for Salmeterol - Fluticasone Dry Powder Inhaler (SPARC DPI) 65
  • 6.5 May 23, 2017: Novartis' new analyses reinforce the potential of Ultibro Breezhaler for COPD patients historically treated with steroids 66
  • 6.6 May 23, 2017: Spiriva Respimat improves breathing for people with asthma regardless of BMI or allergic status 67
  • 6.7 May 23, 2017: Sunovion Announces Utibron Neohaler (indacaterol/glycopyrrolate) Inhalation Powder Data Showing Lung Function and Health-Related Quality of Life Improvement in Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease 67
  • 6.8 May 15, 2017: Sunovion to Present Data on Utibron Neohaler at the American Thoracic Society 2017 International Conference 69
  • 6.9 May 11, 2017: Teva Reports First Quarter 2017 Financial Results 70
  • 6.10 May 10, 2017: MannKind Reports 2017 First Quarter Financial Results 74
  • 6.11 May 09, 2017: OPKO Health Reports 2016 Financial and Operating Results 75
  • 6.12 May 09, 2017: Nektar Therapeutics Reports Financial Results for the First Quarter of 2017 76
  • 6.13 May 08, 2017: Dr. Stephen S. Lane joins Alcon as Chief Medical Officer and Global Head Franchise Clinical Strategy 79
  • 6.14 May 05, 2017: Relvar Ellipta Significantly Improved Asthma Control in Salford Lung Study Patients Compared with Their Usual Care 79
  • 6.15 Apr 26, 2017: Teva Announces Planned Departure of Eyal Desheh, Group Executive Vice President and Chief Financial Officer 82
  • 6.16 Apr 26, 2017: Orion Group Interim Report January-March 2017 82
  • 6.17 Apr 26, 2017: GSK delivers another quarter of continued progress 83
  • 6.18 Apr 25, 2017: Novartis delivered sales growth across all divisions as growth drivers, including Cosentyx and Entresto, more than offset generic erosion; innovation momentum continued 86
  • 6.19 Apr 20, 2017: Teva Launches AirDuo RespiClick and its Authorized Generic, Two Inhalers Containing Fluticasone Propionate and Salmeterol 90
  • 6.20 Apr 04, 2017: GSK responds to Cyclone Debbie 91
  • 6.21 Apr 03, 2017: Sunovion Announces Utibron Neohaler (indacaterol/glycopyrrolate) Inhalation Powder Now Available in the United States 92
  • 6.22 Mar 31, 2017: Verona Pharma Has Developed Its First-In-Class Product Candidate RPL554 As Dry Powder Inhaler 92
  • 6.23 Mar 21, 2017: Pulmatrix Receives European Patent for its Inhaled Drug Delivery Technology 93
  • 6.24 Mar 21, 2017: Vectura Group: Preliminary Results for the nine-month period ended 31 December 2016 94
  • 6.25 Mar 21, 2017: Vectura Group Announces Preliminary Results for the nine-month period ended 31 December 2016 95
  • 6.26 Mar 16, 2017: MannKind Reports 2016 Fourth Quarter and Full Year Financial Results 96
  • 6.27 Mar 06, 2017: Vectura Group: Board Change 98
  • 6.28 Mar 03, 2017: OPKO Health Appoints Dr. Akhtar Ashfaq as Renal Division Senior Vice President, Clinical Research and Development 98
  • 6.29 Mar 01, 2017: OPKO Health Reports 2016 Financial and Operating Results 98
  • 6.30 Mar 01, 2017: Nektar Therapeutics Reports Fourth Quarter and Year-End 2016 Financial Results 100
  • 6.31 Feb 28, 2017: Novartis shareholders approve all resolutions proposed by Board of Directors at the Annual General Meeting 102
  • 6.32 Feb 22, 2017: Otsuka Pharmaceutical Certified as Excellent Health and Productivity Management Enterprise 102
  • 6.33 Feb 16, 2017: FDA Expands Approval of SPIRIVA RESPIMAT (tiotropium bromide) Inhalation Spray for Maintenance Treatment of Asthma in Children 103
  • 6.34 Feb 16, 2017: Vectura achieves £9 million royalty cap from GSK Ellipta® products 104
  • 6.35 Feb 16, 2017: GSK and EMBL have signed an agreement to enhance understanding of disease and drug mechanisms 104
  • 6.36 Feb 13, 2017: Teva Reports Full Year and Fourth Quarter 2016 Financial Results 105
  • 6.37 Feb 13, 2017: Change in Orion Group Executive Management Board as of 21 February 2017 112
  • 6.38 Feb 08, 2017: Orion Group Financial Statement Release for 2016 112
  • 6.39 Feb 08, 2017: GlaxoSmithKline: Results announcement for the fourth quarter 2016 116
  • 6.40 Feb 06, 2017: Teva Appoints Dr. Yitzhak Peterburg as Interim Chief Executive Officer, Succeeding Erez Vigodman 135
  • 6.41 Jan 30, 2017: Teva Announces FDA Approval of New AirDuo RespiClick Maintenance Inhalers for the Treatment of Asthma 137
  • 6.42 Jan 30, 2017: Teva Announces FDA Approval of New ArmonAir RespiClick for the Treatment of Asthma 138
  • 6.43 Jan 27, 2017: Reijo Salonen, Senior Vice President, Pharmaceutical R&D, is CTO of the Year 2017 139
  • 6.44 Jan 26, 2017: Novartis highlights progress towards access and environmental goals in 2016 Corporate Responsibility Performance Report 140
  • 6.45 Jan 26, 2017: Achievement of sales milestone for COPD products 141
  • 6.46 Jan 25, 2017: Novartis delivered solid 2016 performance, with Growth Products absorbing Gleevec US LOE; innovation momentum continued; announces share buyback 141
  • 6.47 Jan 19, 2017: Abbas Hussain to leave GSK 148
  • 6.48 Jan 19, 2017: Luke Miels appointed President, Global Pharmaceuticals, GSK 149
  • 6.49 Jan 11, 2017: Vectura Group: Pre-close update 149
  • 6.50 Jan 06, 2017: Teva Provides 2017 Financial Outlook 151
  • 6.51 Jan 04, 2017: MannKind Announces Key Addition to Its Executive Management Ranks 152
  • 6.52 Jan 03, 2017: MannKind Receives $1 Million Milestone From RLS 153
  • 6.53 Dec 22, 2016: Teva Reaches Settlement with Government on FCPA 153
  • 6.54 Dec 22, 2016: Teva Pharmaceutical Paying $519 Million to Settle FCPA Charges 154
  • 6.55 Dec 21, 2016: Orion is planning to apply for a marketing authorisation for combined salmeterol-fluticasone formulation of the Easyhaler product family 154
  • 6.56 Dec 19, 2016: Pulmatrix Receives Patents Important to its Inhaled Drug Delivery Technology 155
  • 6.57 Dec 19, 2016: OPKO Health to be Added to the NASDAQ Biotechnology Index 155
  • 6.58 Dec 19, 2016: GSK announces Board changes 156
  • 6.59 Dec 14, 2016: Consort Medical: Directorate Change 156
  • 6.60 Dec 08, 2016: Novartis' Ultibro Breezhaler Improved Lung Function And COPD Symptoms After Direct Switch From Previous Treatment 156
  • 6.61 Dec 06, 2016: Consort Medical Reports Interim Results Results For The Six Months Ended 31 October 2016 157
  • 6.62 Dec 05, 2016: Teva Appoints Dipankar Bhattacharjee as President and Chief Executive Officer, Global Generic Medicines Group, Succeeding Siggi Olafsson 160
  • 6.63 Dec 01, 2016: Nanotherapeutics appoints president and CEO 161
  • 6.64 Nov 29, 2016: Novartis Access shares one-year learnings and announces memorandum of understanding with Rwanda 162
  • 6.65 Nov 25, 2016: Consort Medical: CFO Appointment 163
  • 6.66 Nov 21, 2016: GSK files regulatory submission in US for once-daily closed triple combination therapy FF/UMEC/VI for patients with COPD 163
  • 6.67 Nov 15, 2016: Teva Reports Third Quarter 2016 Results 164
  • 6.68 Nov 09, 2016: MannKind Reports 2016 Third Quarter Financial Results 166
  • 6.69 Nov 08, 2016: Teva Announces Appointment of New Chief Legal Officer 168
  • 6.70 Nov 07, 2016: OPKO Health Reports Third Quarter Financial and Operating Results 168
  • 6.71 Nov 03, 2016: Nektar Therapeutics Reports Financial Results for the Third Quarter of 2016 170
  • 6.72 Oct 26, 2016: GlaxoSmithKline: Results Announcement for the third quarter 2016 172
  • 6.73 Oct 25, 2016: Novartis delivered solid third quarter with Growth Products offsetting Gleevec patent expiration; several positive readouts for potential blockbusters 178
  • 6.74 Oct 25, 2016: Orion Group Interim Report January-September 2016 185
  • 6.75 Oct 17, 2016: New Data Analyses Provide Insights That May Help Predict COPD Exacerbation Risk 186
  • 6.76 Oct 12, 2016: New Support Program Provides Free Medicine and Resources for People Living with COPD Prescribed STIOLTO RESPIMAT (tiotropium bromide and olodaterol) Inhalation Spray 188
  • 6.77 Sep 29, 2016: GlaxoSmithKline appoints Brian McNamara as CEO of GSK Consumer Healthcare 189
  • 6.78 Sep 20, 2016: Emma Walmsley to succeed Andrew Witty as Chief Executive Officer of GlaxoSmithKline 190
  • 6.79 Sep 13, 2016: OPKO Health Appoints Jane Pine Wood as Chief Legal and Compliance Officer of BioReference Laboratories 190
  • 6.80 Sep 06, 2016: Tiotropium RESPIMAT Improved Lung Function with Safety Comparable to Placebo in Children with Asthma 191
  • 6.81 Sep 05, 2016: Simple Blood Test Combined with Exacerbation History May Help to Identify When to Add ICS to COPD Treatment 192
  • 6.82 Aug 17, 2016: Consort Medical Announces Directorate Change 193
  • 6.83 Aug 11, 2016: Asembia to Provide HUB and Patient Support Services for MannKind Corporation Related to Afrezza (insulin human) Inhalation Powder 193
  • 6.84 Aug 11, 2016: Breathing Easier: Pharma Successfully Leveraging Smoother EU Regulatory Specs 194
  • 6.85 Aug 08, 2016: OPKO Health Reports Improved Financial and Operating Results 195
  • 6.86 Aug 08, 2016: MannKind Reports 2016 Second Quarter Financial Results 196
  • 6.87 Aug 04, 2016: Teva Reports Second Quarter 2016 Results 197
  • 6.88 Aug 03, 2016: Adamis Pharmaceuticals Strengthens Patent Portfolio for its Dry Powder Inhaler 202
  • 6.89 Aug 03, 2016: Nektar Therapeutics Reports Financial Results for the Second Quarter of 2016 203
  • 6.90 Aug 03, 2016: Former Gates Foundation and Baxter Executive Peter H. Khoury, Ph.D. Joins Nanotherapeutics as Chief Commercial Officer 204
  • 6.91 Aug 01, 2016: Mannkind Assumes Responsibility for Distribution of Afrezza and Launches Patient Reimbursement and Adherence Support Programs 205
  • 6.92 Jul 27, 2016: GSK announces significant new investment in UK manufacturing network 207
  • 6.93 Jul 27, 2016: GlaxoSmithKline: Results announcement for the second quarter 2016 and half-yearly financial report for the half-year 2016 207
  • 6.94 Jul 21, 2016: Meda: Interim Report, January-June 2016 225
  • 6.95 Jul 19, 2016: Novartis delivered solid Q2 despite full quarter of US Gleevec generic impact; significant positive innovation news strengthens future growth prospects 226
  • 6.96 Jul 19, 2016: Orion Group Half-Yearly Report January-June 2016 233
  • 6.97 Jul 15, 2016: PhRMA Welcomes Five New Member Companies 240
  • 6.98 Jul 11, 2016: 3M Announces New Leadership Appointments 240
  • 6.99 Jul 08, 2016: Dr John Brown, Non-Executive Director, confirms date to step down 241
  • 6.100 Jul 07, 2016: GSK and Save the Children call for developing country innovations to enter $1 million award 241
  • 6.101 Jul 06, 2016: Pulmatrix's iSPERSE Focus of Interview with News Medical 242

7 Appendix 243

  • 7.1 Methodology 243
  • 7.2 About GlobalData 246
  • 7.3 Contact Us 246
  • 7.4 Disclaimer 246

List of Tables

1.1 List of Tables

  • Table 1: Dry Powder Inhaler Devices - Pipeline Products by Stage of Development 11
  • Table 2: Dry Powder Inhaler Devices - Pipeline Products by Territory 12
  • Table 3: Dry Powder Inhaler Devices - Pipeline Products by Regulatory Path 13
  • Table 4: Dry Powder Inhaler Devices - Pipeline Products by Estimated Approval Date 14
  • Table 5: Dry Powder Inhaler Devices - Ongoing Clinical Trials 15
  • Table 6: Dry Powder Inhaler Devices Companies - Pipeline Products by Stage of Development 16
  • Table 7: Dry Powder Inhaler Devices - Pipeline Products by Stage of Development 18
  • Table 8: Acorda Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 19
  • Table 9: CVT-301 Drug Delivery Device - Product Status 19
  • Table 10: CVT-301 Drug Delivery Device - Product Description 19
  • Table 11: CVT-427 Drug Delivery Device - Product Status 20
  • Table 12: CVT-427 Drug Delivery Device - Product Description 20
  • Table 13: Acorda Therapeutics Inc - Ongoing Clinical Trials Overview 21
  • Table 14: CVT-301 Drug Delivery Device - A 12 Month, Dose-level Blinded Study Investigating the Safety and Efficacy of CVT 301 (Levodopa Inhalation Powder) in Parkinson's Disease Patients with Motor Response Fluctuations (OFF Phenomena) 22
  • Table 15: Adamis Pharmaceuticals Corp Pipeline Products & Ongoing Clinical Trials Overview 23
  • Table 16: Taper DPI - Product Status 23
  • Table 17: Taper DPI - Product Description 23
  • Table 18: Advent Pharmaceuticals Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview 24
  • Table 19: g60 Dry Powder Inhaler - Product Status 24
  • Table 20: g60 Dry Powder Inhaler - Product Description 24
  • Table 21: Aespira Ltd. Pipeline Products & Ongoing Clinical Trials Overview 25
  • Table 22: resQhaler - Product Status 25
  • Table 23: resQhaler - Product Description 25
  • Table 24: AKELA Pharma Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 26
  • Table 25: Fentanyl TAIFUN Inhaler - Product Status 26
  • Table 26: Fentanyl TAIFUN Inhaler - Product Description 26
  • Table 27: Bayer HealthCare AG (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 27
  • Table 28: Ciprofloxacin Dry Powder Inhaler - Product Status 27
  • Table 29: Ciprofloxacin Dry Powder Inhaler - Product Description 27
  • Table 30: Bespak Europe Ltd Pipeline Products & Ongoing Clinical Trials Overview 28
  • Table 31: DEV610 DPI - Product Status 28
  • Table 32: DEV610 DPI - Product Description 28
  • Table 33: Boehringer Ingelheim GmbH Pipeline Products & Ongoing Clinical Trials Overview 29
  • Table 34: Next Generation Respimat Inhaler - Product Status 29
  • Table 35: Next Generation Respimat Inhaler - Product Description 29
  • Table 36: Circassia Pharmaceuticals Plc Pipeline Products & Ongoing Clinical Trials Overview 30
  • Table 37: Tiotropium bromide DPI - Product Status 30
  • Table 38: Tiotropium bromide DPI - Product Description 30
  • Table 39: GlaxoSmithKline Plc Pipeline Products & Ongoing Clinical Trials Overview 31
  • Table 40: ELLIPTA Dry Powder Inhaler - Closed Triple - Product Status 31
  • Table 41: ELLIPTA Dry Powder Inhaler - Closed Triple - Product Description 31
  • Table 42: Gemini Multi-Dose Combination Inhaler - Product Status 32
  • Table 43: Gemini Multi-Dose Combination Inhaler - Product Description 32
  • Table 44: GlaxoSmithKline Plc - Ongoing Clinical Trials Overview 33
  • Table 45: ELLIPTA Dry Powder Inhaler - Closed Triple - A Phase III, Randomized, Double-blind, Active Controlled, Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination FF/UMEC/VI with the Fixed Dose Dual Combination of FF/VI, Administered Once-daily via a Dry Powder Inhaler in Subjects with Inadequately Controlled Asthma 34
  • Table 46: ELLIPTA Dry Powder Inhaler - Closed Triple - A Randomized, Open-label, Cross-over, Placebo-device Study Investigating Critical and Over All Errors, Training/Teaching Time, and Preference Attributes of the ELLIPTA Dry Powder Inhaler (DPI) as Compared to HANDIHALER DPI Used in Combination with Either DISKUS DPI or TURBUHALER DPI, in Adult Patients with Chronic Obstructive Pulmonary Disease (COPD) 34
  • Table 47: ELLIPTA Dry Powder Inhaler - Closed Triple - Description of the Ability to Learn How to Handle Inhaler Devices in Asthma - AUDIT 35
  • Table 48: MannKind Corp Pipeline Products & Ongoing Clinical Trials Overview 36
  • Table 49: Dreamboat - Product Status 36
  • Table 50: Dreamboat - Product Description 36
  • Table 51: Monash University Pipeline Products & Ongoing Clinical Trials Overview 37
  • Table 52: Aerosol Delivery System - Product Status 37
  • Table 53: Aerosol Delivery System - Product Description 37
  • Table 54: Nanotherapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 38
  • Table 55: GelVac Intranasal Powder Vaccine Delivery System - Product Status 38
  • Table 56: GelVac Intranasal Powder Vaccine Delivery System - Product Description 38
  • Table 57: NanoGENT - Product Status 39
  • Table 58: NanoGENT - Product Description 39
  • Table 59: Nektar Therapeutics Pipeline Products & Ongoing Clinical Trials Overview 40
  • Table 60: Nektar Dry Powder Inhaler - Amikacin - Product Status 40
  • Table 61: Nektar Dry Powder Inhaler - Amikacin - Product Description 40
  • Table 62: Novartis AG Pipeline Products & Ongoing Clinical Trials Overview 41
  • Table 63: Seebri Neohaler - Product Status 41
  • Table 64: Seebri Neohaler - Product Description 41
  • Table 65: Ultibro Breezhaler - Product Status 42
  • Table 66: Ultibro Breezhaler - Product Description 42
  • Table 67: Novartis AG - Ongoing Clinical Trials Overview 43
  • Table 68: Ultibro Breezhaler - An Open-label, Low Interventional Clinical Study Investigating Error Rates (Critical and Overall) Prior to any Retraining in Correct use of the ELLIPTA Dry Powder Inhaler (DPI) Compared to other DPIs Including; DISKUS, Turbuhaler, HandiHaler and Breezhaler as a Monotherapy or in Combination, in Adult Patients with Chronic Obstructive Pulmonary Disease (COPD) 44
  • Table 69: Ultibro Breezhaler - The Effectiveness of Single Dose Ultibro Breezhaler (Indacaterol/Glycopyrronium) by Sd-DPI Versus Ipratropium/Salbutamol by Nebulizer in Improving FEV1 and Dyspnea During Stable State of COPD 44
  • Table 70: OPKO Health Inc Pipeline Products & Ongoing Clinical Trials Overview 45
  • Table 71: Inspiromatic - Product Status 45
  • Table 72: Inspiromatic - Product Description 45
  • Table 73: Pharmaxis Ltd Pipeline Products & Ongoing Clinical Trials Overview 46
  • Table 74: Orbital Dry Powder Inhaler - Product Status 46
  • Table 75: Orbital Dry Powder Inhaler - Product Description 46
  • Table 76: Respira Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 47
  • Table 77: RT234 AOS DPI - Product Status 47
  • Table 78: RT234 AOS DPI - Product Description 47
  • Table 79: Sandoz International GmbH Pipeline Products & Ongoing Clinical Trials Overview 48
  • Table 80: Solis Multi-Dose Dry Powder Inhaler - Product Status 48
  • Table 81: Solis Multi-Dose Dry Powder Inhaler - Product Description 48
  • Table 82: Unit-Dose Dry Powder Inhaler - Product Status 49
  • Table 83: Unit-Dose Dry Powder Inhaler - Product Description 49
  • Table 84: Sheffield Hallam University Pipeline Products & Ongoing Clinical Trials Overview 50
  • Table 85: Dry Powder Inhaler - Product Status 50
  • Table 86: Dry Powder Inhaler - Product Description 50
  • Table 87: Shin Nippon Biomedical Laboratories Ltd Pipeline Products & Ongoing Clinical Trials Overview 51
  • Table 88: µco System - Product Status 51
  • Table 89: µco System - Product Description 51
  • Table 90: Sun Pharma Advanced Research Company Ltd Pipeline Products & Ongoing Clinical Trials Overview 52
  • Table 91: SPARC DPI - Product Status 52
  • Table 92: SPARC DPI - Product Description 53
  • Table 93: Teva Pharmaceutical Industries Ltd Pipeline Products & Ongoing Clinical Trials Overview 54
  • Table 94: ArmonAir RespiClick - Product Status 54
  • Table 95: ArmonAir RespiClick - Product Description 54
  • Table 96: Spiromax EU / mDPI US - Product Status 55
  • Table 97: Spiromax EU / mDPI US - Product Description 55
  • Table 98: Teva Pharmaceutical Industries Ltd - Ongoing Clinical Trials Overview 56
  • Table 99: Spiromax EU / mDPI US - Errors in the Use of Turbuhaler and Spiromax Devices Patients with Asthma 57
  • Table 100: ArmonAir RespiClick - 12-Week, Randomized, Double-blind, Placebo-controlled, Efficacy and Safety Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared with Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler in Patients Aged 4 Through 11 Years with Persistent Asthma 58
  • Table 101: University of Kansas Pipeline Products & Ongoing Clinical Trials Overview 59
  • Table 102: Dry Powder Inhaler - Product Status 59
  • Table 103: Dry Powder Inhaler - Product Description 59
  • Table 104: University of Texas Medical Branch at Galveston Pipeline Products & Ongoing Clinical Trials Overview 60
  • Table 105: Dry Powder Drug Delivery System - Product Status 60
  • Table 106: Dry Powder Drug Delivery System - Product Description 60
  • Table 107: Vectura Group Plc Pipeline Products & Ongoing Clinical Trials Overview 61
  • Table 108: SKP-2075 - Product Status 61
  • Table 109: SKP-2075 - Product Description 61
  • Table 110: Verona Pharma Plc Pipeline Products & Ongoing Clinical Trials Overview 62
  • Table 111: RPL554 - Dry Powder Inhaler - Product Status 62
  • Table 112: RPL554 - Dry Powder Inhaler - Product Description 62
  • Table 113: Virginia Commonwealth University Pipeline Products & Ongoing Clinical Trials Overview 63
  • Table 114: Dry Powder Inhaler - Product Status 63
  • Table 115: Dry Powder Inhaler - Product Description 63
  • Table 116: Glossary 245

List of Figures

1.2 List of Figures

  • Figure 1: Dry Powder Inhaler Devices - Pipeline Products by Stage of Development 11
  • Figure 2: Dry Powder Inhaler Devices - Pipeline Products by Territory 12
  • Figure 3: Dry Powder Inhaler Devices - Pipeline Products by Regulatory Path 13
  • Figure 4: Dry Powder Inhaler Devices - Pipeline Products by Estimated Approval Date 14
  • Figure 5: Dry Powder Inhaler Devices - Ongoing Clinical Trials 15
Back to Top